Two Biotechnology Names Are Hot: Mast Therapeutics, Inc. (MSTX), Novavax, Inc. (NVAX)

Two Biotechnology Names Are Hot: Mast Therapeutics, Inc. (MSTX), Novavax, Inc. (NVAX)

Two Biotechnology Names Are Hot: Mast Therapeutics, Inc. (MSTX), Novavax, Inc. (NVAX)

Mast Therapeutics, Inc. (MSTX) ended last trading session with a change of -2.9 percent. It trades at an average volume of 7.43M shares versus 3.1M shares recorded at the end of last trading session. The share price of $0.11 is at a distance of 57.86 percent from its 52-week low and down -84.44 percent versus its peak. The company has a market cap of $27.63M and currently has 250M shares outstanding. The share price is currently -10.4 percent versus its SMA20, -12.53 percent versus its SMA50, and -54.36 percent versus its SMA200. The stock has a weekly performance of -7.14 percent and is 22.78 percent year-to-date as of the recent close.

On March 6, 2017 Mast Therapeutics, Inc. (MSTX) reported financial results for the fourth quarter and year ended December 31, 2016.

“We are pleased with the progress made with AIR001 during the year and anticipate the closing of the merger with Savara to take place in the second quarter of this year,” stated Brian M. Culley, Chief Executive Officer.  “We believe this merger offers our stockholders a diversified, late-stage product development pipeline with important forthcoming milestones.”

Novavax, Inc. (NVAX) recently recorded -1.37 percent change and currently at $1.44 is 24.14 percent away from its 52-week low and down -83.04 percent versus its peak. It has a past 5-day performance of -2.04 percent and trades at an average volume of 6.4M shares. The stock has a 1-month performance of 9.09 percent and is 14.29 percent year-to-date as of the recent close. There were about 271.92M shares outstanding which made its market cap $391.56M. The share price is currently -1.57 percent versus its SMA20, 3.67 percent versus its SMA50, and -61.07 percent versus its SMA200.

On Feb. 27, 2017 Novavax, Inc., (NVAX) announced its financial results for the fourth quarter and twelve months ended December 31, 2016.

Novavax reported a net loss of $57.1 million, or $0.21 per share, for the fourth quarter of 2016, compared to a net loss of $78.8 million, or $0.29 per share, for the fourth quarter of 2015. For the twelve months ended December 31, 2016, the net loss was $280.0 million, or $1.03 per share, compared to a net loss of $156.9 million, or $0.60 per share, for the same period in 2015.

 

Add Comment

Investing is speculative. When investing your capital is at risk. This site is not intended for use in jurisdictions in which the trading or investments described are prohibited and should only be used by such persons and in such ways as are legally permitted. Your investment may not qualify for investor protection in your country or state of residence, so please conduct your own due diligence. This website is free for you to use but we may receive commission from the companies we feature on this site. Click here for more information.